CALC
CalciMedica, Inc.Healthcare · $4M market cap
Verdict
We can't put a fair value on CALC right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow CALC
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Nov 3, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about CALC
Are insiders buying CALC?
Since Nov 3, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar).
How can I check CALC's value myself?
Use the free Sticker Price calculator, already filled with CALC's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 5, 2026. How the Payback Price works